Amneal Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
UPDATE: Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 2c, Revenues Miss; Offers FY21 Revenues Outlook
May 7, 2021 6:09 AM EDT(Updated - May 7, 2021 6:10 AM EDT)
Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Revenue for the quarter came in at $493 million versus the consensus estimate of $513.24 million.
Amneal delivered solid first quarter results, continuing our positive momentum as... More
